[1] Candotti D, Assennato SM, Laperche S, et al. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut,2019,68:313-321.
[2] Pollicino T, Squadrito G, Cerenzia G, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology, 2004, 126: 102-110.
[3] Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut, 2012, 61(Suppl 1): 16-17.
[4] Wong DKH, Huang FY, Lai CL, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryp-togenic cause of hepatocellular carcinoma. Hepatology, 2011, 54: 829-836.
[5] Pollicino T, Raffa G, Costantino L, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology, 2007, 45: 277-285.
[6] 胡伯斌. HBV S基因整合对CHB患者NAs治疗后血清HBsAg水平影响的研究. 广西医科大学,2016.
[7] Penna A, Artini M, Cavalli A, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest, 1996, 98: 1185-1194.
[8] Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Med, 1996, 2: 1104-1108.
[9] Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology, 2012, 143: 963-973.
[10] Zerbini A, Pilli M, Boni C, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology. 2008, 134: 1470-1481.
[11] Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology, 2017, 152: 1297-1309.
[12] Yang R, Song G, Guan W, et al. The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen. J Virol Methods, 2016, 228: 39-47.
[13] Ozeki I, Nakajima T, Suii H, et al. Analysis of hepatitis B surface antigen (HBsAg) using high-sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays. Hepatol Res, 2018, 48: 263-274.
[14] Zhang K, Liu Y, Chen R, et al. Antigenicity reduction contributes mostly to poor detectability of HBsAg by hepatitis B virus (HBV) S-gene mutants isolated from individuals with occult HBV infection. J Med Virol, 2018, 90: 263-267.
[15] Matsumoto A, Imaizumi M, Tanaka Y, et al. Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody. J Gastroenterol, 2016, 52: 376-384.
[16] Akram A, Islam S M R, Munshi S U, et al. Detection of hepatitis B virus DNA among chronic and potential occult HBV patients in resource-limited settings by loop-mediated isothermal amplification assay. J Viral Hepat, 2018, 25: 1306-1311.
[17] Caviglia GP, Abate ML, Tandoi F, et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. J Hepatol, 2018, 69: 301.
[18] Spreafico M, Berzuini A, Foglieni B, et al. Poor efficacy of nucleic acid testing in identifying occult HBV infection and consequences for safety of blood supply in Italy. J Hepatol,2015, 63: 1068-1076.
[19] Hassan ZK, Hafez MM, Mansor TM, et al. Occult HBV infection among Egyptian hepatocellular carcinoma patients. Virol J, 2011, 8: 1-6.
[20] Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol, 2006, 36(Suppl 1): S33-44.
[21] Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol, 2010, 52: 272-279.
[22] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015更新版).肝脏,2015,20:915-932.
[23] Coffin C S, Mulrooney-Cousins PM, Marle GV, et al. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver tran-spl, 2011, 17: 955-962.
[24] Chen ZX, Gu GF, Bian ZL, et al. Clinical course and perinatal transmission of chronic hepatitis B during pregnancy: A real-world prospective cohort study. J Infect, 2017, 75: 146-154.
[25] Sadeghi A, Yahyapour Y, Poortahmasebi V, et al. Clearance of HBV DNA in immunized children born to HBsAg-positive mothers, years after being diagnosed with occult HBV infection. J Viral Hepat, 2016, 23: 282-285.
[26] Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology, 2017, 65: 1451-1461.
[27] Caviglia GP, Abate ML, Tandoi F, et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: a new tool to detect occult infection. J Hepatol, 2018, 69: 301-307. |
